An overview of early investigational therapies for chemoresistant ovarian cancer

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Expert Opinion on Investigational Drugs

• Publication date

  2015-08-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/13543784.2015.1072168PMID 26206420
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

  2015cited by this paper
• A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors

  2015cited by this paper
• Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer

  2015cited by this paper
• Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.

  2015cited by this paper
• Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.

  2015cited by this paper
• Updates and emerging therapies for rare epithelial ovarian cancers: one size no longer fits all.

  2015cited by this paper
• Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study.

  2015cited by this paper
• Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial.

  2015cited by this paper
• Impact of trebananib plus weekly paclitaxel on overall survival (OS) in patients (pts) with recurrent ovarian cancer and ascites: Results from the phase III TRINOVA-1 study.

  2015cited by this paper
• The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.

  2015cited by this paper
• Multicentre trial of carboplatin/paclitaxel versus oxaliplatin/capecitabine, each with/without bevacizumab, as first line chemotherapy for patients with mucinous epithelial ovarian cancer (mEOC).

  2015cited by this paper
• Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.

  2015cited by this paper
• A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma

  2015cited by this paper
• Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies.

  2014cited by this paper
• First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors

  2014cited by this paper
• Incorporation of pazopanib in maintenance therapy of ovarian cancer.

  2014cited by this paper
• A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.

  2014cited by this paper
• A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer.

  2014cited by this paper
• Masitinib (AB1010), from canine tumor model to human clinical development: where we are?

  2014cited by this paper
• Lurbinectedin (PM01183), an active compound in platinum-resistant/refractory ovarian cancer (PRROC) patients: Results of a two-stage, controlled phase II study.

  2014cited by this paper
• Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer.

  2014cited by this paper
• Phase 1/2 study of oral rucaparib: Final phase 1 results.

  2014cited by this paper
• Use of statins and the risk of death in patients with prostate cancer.

  2014cited by this paper
• Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer.

  2014cited by this paper
• A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†.

  2014cited by this paper
• Phase I trial of pegylated liposomal doxorubicin in combination with BIBF 1120 (nintedanib) in platinum-resistant ovarian cancer: Hoosier Oncology Group GYN10-149.

  2014cited by this paper
• Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

  2014cited by this paper
• Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.

  2014cited by this paper
• The Therapeutic Potential of Class I Selective Histone Deacetylase Inhibitors in Ovarian Cancer

  2014cited by this paper
• PI3K and cancer: lessons, challenges and opportunities

  2014cited by this paper
• A phase II study of intermittent sorafenib with bevacizumab (B) in B-naive and prior B-exposed epithelial ovarian cancer (EOC) patients.

  2014cited by this paper
• Ovarian cancer

  2014cited by this paper
• Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.

  2014cited by this paper
• A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma.

  2013cited by this paper
• Masitinib in nonresectable pancreatic cancer: Results of a phase III randomized placebo-controlled trial.

  2013cited by this paper
• Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study

  2013cited by this paper
• Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: a retrospective, multicenter study.

  2013cited by this paper
• First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors

  2013cited by this paper
• Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.

  2013cited by this paper
• Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor

  2013cited by this paper
• The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.

  2013cited by this paper
• Clinical Relevance of Gain-Of-Function Mutations of p53 in High-Grade Serous Ovarian Carcinoma

  2013cited by this paper
• Network Analysis Identifies an HSP90-Central Hub Susceptible in Ovarian Cancer

  2013cited by this paper
• Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.

  2013cited by this paper
• A phase I study of oral rucaparib in combination with carboplatin.

  2013cited by this paper
• Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer

  2013cited by this paper
• Feasibility of long-term patient self-reporting of toxicities from home via the Internet during routine chemotherapy.

  2013cited by this paper
• Phase I study of ABT-888 in combination with carboplatin and gemcitabine in subjects with advanced solid tumors.

  2013cited by this paper
• New perspectives on molecular targeted therapy in ovarian clear cell carcinoma

  2013cited by this paper
• Targeting Src and Tubulin in Mucinous Ovarian Carcinoma

  2013cited by this paper
• Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.

  2013cited by this paper
• Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission

  2012cited by this paper
• Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

  2012cited by this paper
• Lurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer

  2012cited by this paper
• Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer.

  2012cited by this paper
• A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy.

  2012cited by this paper
• Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours

  2012cited by this paper
• Current knowledge and open issues regarding bevacizumab in gynaecological neoplasms.

  2012cited by this paper
• A Phase I, dose‐finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors *,†

  2012cited by this paper
• A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites.

  2012cited by this paper
• Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.

  2012cited by this paper
• Phase II Activity of Belinostat (PXD-101), Carboplatin, and Paclitaxel in Women With Previously Treated Ovarian Cancer

  2012cited by this paper
• Olaparib, PARP1 inhibitor in ovarian cancer

  2012cited by this paper
• A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

  2012cited by this paper
• Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.

  2012cited by this paper
• BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

  2012cited by this paper
• A phase II study of pazopanib in recurrent or persistent ovarian (EOC), peritoneal (PPC), or Fallopian tube cancer (FTC): A Spanish Ovarian Cancer Group (GEICO) study.

  2012cited by this paper
• Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.

  2012cited by this paper
• Brivanib (B) in Advanced Ovarian Cancer (OC): Subset Results of a Phase 2 Randomized Discontinuation Trial (RDT)

  2012cited by this paper
• High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody.

  2011cited by this paper
• Clinical Trials in Recurrent Ovarian Cancer

  2011cited by this paper
• Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study.

  2011cited by this paper
• Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.

  2011cited by this paper
• Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

  2011cited by this paper
• Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT).

  2011cited by this paper
• Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

  2011cited by this paper
• Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group.

  2011cited by this paper
• Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

  2011cited by this paper
• OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.

  2011cited by this paper
• A phase 3 trial of bevacizumab in ovarian cancer.

  2011cited by this paper
• Incorporation of bevacizumab in the primary treatment of ovarian cancer.

  2011cited by this paper
• Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.

  2011cited by this paper
• IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer

  2011influential reference
• Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer.

  2011cited by this paper
• Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.

  2011cited by this paper
• Pazopanib

  2011cited by this paper
• A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study.

  2011cited by this paper
• Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2–Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors

  2010cited by this paper
• Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

  2010cited by this paper
• Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2

  2010cited by this paper
• First-line treatment of advanced ovarian cancer: current research and perspectives

  2010cited by this paper
• Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents.

  2010cited by this paper
• Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.

  2010cited by this paper
• Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial

  2010cited by this paper
• A phase I pharmacological and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.

  2010cited by this paper
• Vascular Endothelial Growth Factor Is a Promising Therapeutic Target for the Treatment of Clear Cell Carcinoma of the Ovary

  2010cited by this paper
• Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer

  2010cited by this paper
• A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer.

  2010cited by this paper

• Pharmacological inhibition of KDM1A/LSD1 enhances estrogen receptor beta-mediated tumor suppression in ovarian cancer.

  2023cites this paper
• Therapeutic Targeting of Ovarian Cancer Stem Cells Using Estrogen Receptor Beta Agonist

  2022cites this paper
• Developing a Prognostic Gene Panel of Epithelial Ovarian Cancer Patients by a Machine Learning Model

  2019cites this paper
• Epithelial ovarian cancer.

  2019cites this paper
• Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-β1-induced EMT and confers paclitaxel resistance in ovarian cancer

  2018cites this paper
• Targeting estrogen receptor beta (ERβ) for treatment of ovarian cancer: importance of KDM6B and SIRT1 for ERβ expression and functionality

  2018cites this paper
• CDH1, DLEC1 and SFRP5 methylation panel as a prognostic marker for advanced epithelial ovarian cancer.

  2018cites this paper
• Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer.

  2018cites this paper
• Epithelial ovarian cancer

  2018cites this paper
• Overcoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapies

  2017cites this paper
• Short-Infusion Trabectedin in Heavily Pretreated Ovarian Cancer Patients: A Single-Institution Experience

  2017cites this paper
• The clinicopathological parameters significance of CD133 and Nestin in epithelial ovarian cancer: a meta-analysis.

  2017cites this paper
• Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer

  2016cites this paper
• PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research.

  2016cites this paper
• Bevacizumab in Ovarian Cancer: State of the Art and Unanswered Questions

  2016cites this paper
• Role of Wnt/β-catenin, Wnt/c-Jun N-terminal kinase and Wnt/Ca2+ pathways in cisplatin-induced chemoresistance in ovarian cancer

  2016cites this paper
• New perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes

  2016cites this paper